<i>In Vitro</i> Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients
Andrej Lissat(Charité - Universitätsmedizin Berlin), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Martin Stanulla(Leibniz University Hannover), André Baruchel(Université Paris Cité), Roberta La Starza(University of Perugia), Julia Alten(Christian-Albrechts-Universität zu Kiel), Martin Schrappe(University Hospital Schleswig-Holstein), Francesco Ceppi(University of Lausanne), Silvia Jenni(University Children's Hospital Zurich), Ondřej Hrušák(Charles University), Andreas E. Kulozik(Heidelberg University), Gunnar Cario, Despina Maniotis(University Children's Hospital Zurich), C. Michel Zwaan(Princess Máxima Center), Michael Nosswitz(University Children's Hospital Zurich), Arend von Stackelberg(Charité - Universitätsmedizin Berlin), Elad Jacoby(Edmond and Lily Safra Children's Hospital), Cornelia Eckert(Humboldt-Universität zu Berlin), Yi-Chien Tsai, Axel Karow, Olaf Witt(German Cancer Research Center), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 1
Related Papers
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606